Page last updated: 2024-08-23

tetradecanoylphorbol acetate and gefitinib

tetradecanoylphorbol acetate has been researched along with gefitinib in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ao, Y; Fukumoto, H; Kuroki, T; Mori, M; Naruse, I; Nishio, K; Ohmori, T; Saijo, N1

Other Studies

1 other study(ies) available for tetradecanoylphorbol acetate and gefitinib

ArticleYear
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    International journal of cancer, 2002, Mar-10, Volume: 98, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; K562 Cells; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphorylation; Quinazolines; RNA, Neoplasm; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

2002